Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
African horsesickness virus serotype 4 (AHSV-4) outer-capsid proteins VP2 or VP2 and VP5, prepared from single or dual recombinant baculovirus expression vectors grown in Sf9 insect cells, were administered in different amounts to horses and the neutralizing antibody responses were measured. Control and vaccinated horses were challenged with virulent AHSV-4 6 months later and monitored post challenge. The results indicated that two inoculations of extracts containing VP2 and VP5, or VP2 alone, in doses of 5 micrograms VP2 or more per horse, were sufficient to elicit protection against African horsesickness (AHS) disease. The recombinant VP2 protein is a potential candidate vaccine for AHS in horses.
Roy
P
P
Laboratory of Molecular Biophysics, University of Oxford, UK. por@mail.nerc-oxford.ac.uk
Bishop
D H
DH
Howard
S
S
Aitchison
H
H
Erasmus
B
B
D000355:African Horse Sickness / Q000276:immunology / Q000517:prevention & control*; D000356:African Horse Sickness Virus / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D002213:Capsid / Q000235:genetics / Q000276:immunology*; D036022:Capsid Proteins; D002460:Cell Line; D002642:Chick Embryo; D006736:Horses; D009500:Neutralization Tests; D017924:Nucleopolyhedroviruses / Q000235:genetics; D018411:Spodoptera / Q000166:cytology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; C442519:VP2 protein, African horse sickness virus; C442560:VP5 protein, African horse sickness virus; D014614:Vaccines, Synthetic; D014765:Viral Vaccines